EFFECTS OF BRL-47672 ON GROWTH, BETA(2)-ADRENOCEPTORS, AND ADENYLYL-CYCLASE ACTIVATION IN FEMALE RATS

Citation
Mn. Sillence et al., EFFECTS OF BRL-47672 ON GROWTH, BETA(2)-ADRENOCEPTORS, AND ADENYLYL-CYCLASE ACTIVATION IN FEMALE RATS, American journal of physiology: endocrinology and metabolism, 31(1), 1995, pp. 159-167
Citations number
29
Categorie Soggetti
Physiology
ISSN journal
01931849
Volume
31
Issue
1
Year of publication
1995
Pages
159 - 167
Database
ISI
SICI code
0193-1849(1995)31:1<159:EOBOGB>2.0.ZU;2-2
Abstract
The morpholine compound BRL-47672 has a chemical structure similar to that of clenbuterol and causes similar anabolic effects in rats but ha s no actions on beta(2)-adrenoceptors in vitro. It has been argued the refore that beta(2)-adrenoceptors do not mediate the anabolic effects of this family of compounds. In the present study BRL-47672 was shown to bind to rat beta(2)-adrenoceptors with low affinity (dissociation c onstant 16 mu M) relative to clenbuterol (48 nM) and to be a very weak activator of adenylyl cyclase activity in rat skeletal muscle membran es in vitro. In contrast, acute administration of the drug to anesthet ized rats in vivo caused an increase in muscle adenosine 3',5'-cyclic monophosphate output, and chronic treatment of conscious rats for >6 d ays caused a significant increase in weight gain (69%) accounted for b y increased muscle growth. The anabolic effects of BRL-47672 were not counteracted by daily injections of the drug ICI-118551 (2 mg/day) but were prevented when the same beta(2)-antagonist was administered in t he diet (200 mg/kg feed, equivalent to 4.3 mg/day). The beta(1)-adreno ceptor selective antagonist CGP-20712A fed in the diet (200 mg/kg feed ) failed to attenuate the response to BRL-47672. These results support the conclusion that BRL-47672 has little direct action on beta(2)-adr enoceptors but suggest that the compound is metabolized rapidly in viv o to a potent beta(2)-agonist. Thus the stimulation of muscle growth b y BRL-47672 is via beta(2)-adrenoceptors, with no contribution to this response from beta(1)- or beta(3)-adrenoceptor activation.